A Phase I, Open-Label, Multicentre Study to Compare Two Dosage Formulations of AZD5363 and to Establish the Effect of Food on the Pharmacokinetic Exposure, Safety and Tolerability of AZD5363 in Patients With Advanced Solid Malignancies

Trial Profile

A Phase I, Open-Label, Multicentre Study to Compare Two Dosage Formulations of AZD5363 and to Establish the Effect of Food on the Pharmacokinetic Exposure, Safety and Tolerability of AZD5363 in Patients With Advanced Solid Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2016

At a glance

  • Drugs AZD 5363 (Primary) ; AZD 5363 (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Acronyms OAK
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2016 Study design has been changed. Time frame for primary endpoints changed.
    • 30 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 02 Jun 2015 Interim results in 23 patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top